Electromed (NYSE:ELMD) Raised to "Strong-Buy" at Roth Capital

Electromed (NYSE:ELMD - Get Free Report) was upgraded by equities researchers at Roth Capital to a "strong-buy" rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the stock. B. Riley raised shares of Electromed to a "strong-buy" rating in a research report on Thursday, May 15th. Wall Street Zen downgraded shares of Electromed from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th.

Electromed Trading Up 3.1%

NYSE ELMD opened at $18.69 on Monday. The business's 50-day moving average price is $20.38 and its 200 day moving average price is $24.74. Electromed has a twelve month low of $13.74 and a twelve month high of $35.56. The company has a market capitalization of $156.73 million, a PE ratio of 24.92 and a beta of 0.41.

Institutional Trading of Electromed

Institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC lifted its position in Electromed by 7.8% during the 4th quarter. Squarepoint Ops LLC now owns 11,366 shares of the company's stock worth $336,000 after buying an additional 823 shares in the last quarter. Aristides Capital LLC increased its position in Electromed by 4.7% in the fourth quarter. Aristides Capital LLC now owns 26,076 shares of the company's stock worth $771,000 after purchasing an additional 1,159 shares during the period. Russell Investments Group Ltd. acquired a new stake in Electromed in the fourth quarter worth about $37,000. Quantbot Technologies LP increased its position in Electromed by 57.7% in the first quarter. Quantbot Technologies LP now owns 5,301 shares of the company's stock worth $126,000 after purchasing an additional 1,939 shares during the period. Finally, State of Wyoming acquired a new stake in Electromed in the first quarter worth about $48,000. 40.82% of the stock is currently owned by institutional investors and hedge funds.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.